Close Menu

Technion - Israel Institute of Technology

While new ways to carry out pool testing for SARS-CoV-2 abound, questions remain about sensitivity issues and the regulation of such tests.

The Israeli institute will share its expertise on translating research into commercially viable applications with the goal of advancing personalized medicine.

Researchers are developing a nanopore sensing device that relies on restriction enzymes to target specific clinically relevant variants in pathogens. 

Technion's Reut Shalgi is building up her lab to study how chaperones affect protein synthesis and protein folding.

The majority of the funding will be used to establish a cancer metabolomics research center on Technion's campus. 

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.

CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.

Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.

In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.